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Cancer research has undergone radical changes over the last few years. The issue today is no longer
the amount of molecular, cellular, and clinical information available, but how to handle it. Systems
biology is the latest in a series of innovative strategies driven by technological advances that have
provided us with a suite of “omics” (1). Technology advancements have enabled comprehensive
characterization of genomic, epigenomic, transcriptomic, proteomic, and metabolomic alterations
in tumor specimens (2). Despite this continuous progress, prostate cancer remains a major public
health problem throughout the world (3). Among men, cancers of the prostate, lung and bronchus,
and colon–rectum will account for about 50% of all newly diagnosed cancer (4). Prostate-specific
antigen (PSA) is one of the most widely used tumor markers. Although its possible use in early
diagnosis or screening PSA has various drawbacks mainly due to its low specificity (5) considering
that more than half of the men with PSA over 4.0 ng/ml are negative on initial biopsy (6). A new
generation of biomarkers is emerging, consisting of genomic-, serum-, urine-, and tissue-based
assays that may supplement PSA testing, or replace it over time (7–9). Although the identification
and development of more specific diagnostic biomarkers are considered important, the major focus
in translational prostate cancer research is the identification of potential “quantitative variables”
to detect clinically significant prostate cancers. As reported by Vlaeminck-Giullem et al. (10), the
current dilemma is to specifically distinguish among all prostate tumors the very aggressive high-
grade cancers that will become life threatening by developing extra-prostatic invasion andmetastatic
potential from the indolent cancers that will never modify a patient’s life expectancy. At molecular
level, Src and other members of the Src kinase family have been proposed as potential candidates
(10). Recently, it has been shown that the activation of Src-dependent intracellular pathways is
frequently observed in clinically significant prostate cancer (11). The proto-oncogene tyrosine-
protein kinase Src influences some of most important events that accompany tumor progression,
including cell proliferation, cell motility, invasion, epithelial-to-mesenchymal transition, resistance
to apoptosis, angiogenesis, neuroendocrine differentiation, and metastatic diffusion (11). The
particularity of the Src oncogenic action in prostate carcinogenesis is its ability to interfere with
the androgen pathway. Through both direct and indirect interaction with the androgen receptor
(AR), Src reinforce the proliferative and anti-apoptotic actions of the AR, even in the absence of
specific ligands. These molecular mechanisms constitute a solid rationale in favor of the use of Src
inhibitors inmanaging patientswith prostate cancer (10, 12).On the other hands, decades of research
are now leading to therapeutics that target themolecularmechanisms of the cancer-specific immune
response (13). These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants
that activate innate immunity, adoptive cellular therapy, and checkpoint blockade (13). Another
major effort has been in prostate cancer prevention, where blockade of the testosterone metabolism
pathway may be a major focus. However, the results of two large randomized, placebo-controlled
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trials: the prostate cancer prevention trial (PCPT) with finas-
teride and the reduction by dutasteride of prostate cancer events
(REDUCE) trial have fueled controversies on the use of 5α-
reductase inhibitors (5-ARI). Finasteride and dutasteride are
among the agents used to target the androgen–AR axis to pre-
vent the development and/or progression of prostate cancer, as
summarized by Kosaka et al. (14). In particular, 5-ARIs have been
shown to play a potential role in preventing clinical progression
among men with low-risk prostate cancer on active surveillance.
However, in light of the US Food and Drug Administration
recommendation against 5-ARIs for primary chemoprevention,
these findings should be interpreted with caution (3, 15).
It is recognized that prostate cancer canmainly be diagnosed on
the basis of increased PSA levels associated with a low accuracy of
the randomly sampled biopsy fragments and the well-known sub-
jectivity of a pathologist’s interpretation (16). New imaging strate-
gies include multiparametric magnetic resonance imaging (MRI)
andMRI/ultrasound (US) fusion.MultiparametricMRI combines
T2-weighted imaging, diffusion weighted imaging, and perfusion
imaging. Published data suggest thatmultiparametricMRI guided
biopsy results in the increased detection of more clinically sig-
nificant high-grade cancers, with lower detection of low-grade
clinically indolent cancers (16, 17). However, a high prevalence of
both overuse and underuse of guideline-recommended imaging
in prostate cancer has been observed, and additional research
is required to examine contributing factors to guideline non-
adherence in the imaging work-up of prostate cancer (18). As
reported by Giannarini et al. (19), multiparametric MRI should
be further evaluated in different clinical scenarios in which it
is desirable to reduce the proportion of unnecessary prostate
biopsies and to limit the detection of indolent disease, such as
opportunistic screening, persistent prostate cancer suspicion in
men with previous negative prostate biopsies, and eligibility for
active surveillance. Continued improvement in standardization of
technical parameters, functional sequences, and image reporting
systems is a pre-requisite for a rapid and successful dissemination
of this imaging modality (19). Recently, Hoeks et al. performed
in-bore MRI guided biopsies in 265 patients with elevated PSA
and previous negative TRUS-guided biopsies (20). Prostate cancer
was found in 41% of patients and the majority of the detected
cancers (87%) were clinically significant (20). However, in-bore
MRI guided biopsies have some limitations, including discomfort
related to patient position, increased costs related to long pro-
cedure duration, and the requirement for special non-magnetic
equipment (17). Furthermore, the actual classification of very
low-, low-, intermediate-, and high-risk disease is only accurate
in the case of patients with high-risk disease. Other factors such
as early detection, population aging, and better treatment have
contributed to increasing the prevalence of prostate cancer, thus
fueling a need for the continuous monitoring of prevalence indi-
cators in order to identify needs, plan the allocation of resources,
and improve healthcare programs for cancer survivors.
Angiogenesis, the development of new branching vessels from
existing vasculature, is a complex process observed in fetal
growth, wound healing, endometrial hyperplasia associated with
the menstrual cycle, and in many diseases, including cancer (21).
The significance of angiogenesis in prostate cancer still remains
controversial (22–24). Štifter and Dordević (25) try to express
opinion that in near future we should search for the next gener-
ation of promising therapeutics for the management of prostate
cancer. Till now, several agents have been approved by the food
and drugs administration (FDA) but their efficacy is still limited
and this observation is repeatedly proven by recurrence of more
aggressive tumor after application of anti-angiogenic therapy (25).
Alternatively, they proposed two options of therapeutic actions,
one targeting reactive stroma and other is aiming at inflammatory,
stromal, and circulating cells (25).
The Research Topic entitled “Prostate Cancer: what we know
andwhat we would like to know” has highlighted somemolecular,
cellular, clinical, epidemiological, and imaging findings that are
fundamental for identifying the patients who are in most need of
aggressive therapeutic intervention, viewing prostate cancer as a
system that is dynamically complex. It is now widely accepted that
prostate cancer encompasses various pathological entities and a
wide range of clinical behaviors, and is underpinned by a complex
array of genetic alterations that affect supra-molecular processes
(26, 27). It is this genetic and phenotypical variability that primar-
ily determines the progression of prostate cancer and its response
to therapy. Furthermore, the asynchrony and self-progression of
prostate cancer cell populations suggests that the extent to which
each neoplastic cell shares the properties of a natural cell differs
in terms of time and space. Individual cells from a clonal cell
population may respond differently (or not at all) to the same
stimulus. Prostate cancer consists of distinct subpopulations of
cancer cells, each with its own characteristic sensitivity to a given
therapeutic agent. Cancer therapies can therefore be seen as filters
that remove the sensitive subpopulations, but allow insensitive
subpopulations to escape (28). Noteworthy, in 2011, Cornù et al.
have shown that dogs can be trained to detect prostate cancer by
smelling urine with a significant success rate (29). By analyzing
33 patients with prostate cancer, they reported a sensitivity and
specificity of 91%, and suggested that prostate cancer gives an odor
signature to urine (29). Recently, Taverna et al. (30) established
that a trained canine olfactory system can detect prostate cancer-
specific volatile organic compounds (VOCs) in urine samples.
Their study included 902 subjects (362 with prostate cancer rang-
ing from very low risk to metastatic and 540 healthy, affected
by non-neoplastic diseases or non-prostate cancer control partic-
ipants). The urine samples from both groups were blinded and
analyzed by two dogs, and the sensitivity, specificity of each dog’s
efficiency was assessed. The first dog achieved a sensitivity of
100% and a specificity of 98%. The second dog reached 98.6%
specificity, 97.6% sensitivity (30). These data encourage all of
us to redouble our efforts to improve the detection of prostate
cancer (31). Unanswered questions, however, remains, including
what does the dogs smell? Further studies should be designed to
research whether a single odor or a mixture of prostate cancer-
specific VOCs are recognized by the dogs. Another question is:
“How could a dog that detects prostate cancer-specific VOCs
be used in daily practice?” The potential predictive power of
this method needs to be additionally investigated by studying
patients with negative biopsies, elevated PSA serum value, and
an adequate follow-up. It has been stated that the identification
of the VOCs could lead to a potentially useful screening tool for
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prostate cancer (29). Additionally, this approach might have the
potential to offer a non-invasive alternative to PSA sampling and
prostate biopsy for detecting prostate cancer (32). It is known
that biomarkers are features that can be objectively measured and
evaluated as indicators of normal processes, pathogenic processes,
or pharmacologic responses to a therapeutic intervention, and
that biomarkers can be clinical parameters, laboratory measures,
imaging-based measures, or genetic and molecular determinants.
It is indubitable that the combined efforts of urologists, oncolo-
gists, pathologists, biologists, radiotherapists, andmathematicians
can contribute much toward improving our understanding of the
complexity of cancer, and such a multidisciplinary approach will
help to clarify existing concepts, categorizes current knowledge,
and suggest alternative approaches to the discovery of biomarkers
and predictive values that urgently need to be translated into
clinical practice.
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